Get the latest recommendations on COVID-19 diagnostics and testing, and how to improve testing capacity in low-income settings.
Summary of current WHO recommendations and guidance on programmatic approaches
Stellungnahme der Arbeitsgruppe AWMFLeitlinie Tuberkulose im Kindes- und Jugendalter: Diagnostik, Prävention und Therapie unter Federführung der Deutschen Gesellschaft für Pädiatrische Infektiologie.
Monatsschr Kinderheilkd 2015 · 163:1287–1292 DOI 10.1007/s00112-015-0007-5 © Deutsche Gesel...lschaft für Pädiatrische
Infektiologie 2015
more
This interactive website provides detailed information on current and past BCG policies and practices for over 180 countries. The Atlas is designed to be a useful resource for clinicians, policymakers and researchers alike, providing information that may be helpful for better interpretation of TB di...agnostics as well as design of new TB vaccines
more
Background: Cardiovascular disease (CVD), mainly heart attack and stroke, is the
leading cause of premature mortality in low and middle income countries (LMICs).
Identifying and managing individuals at high risk of CVD is an important strategy to prevent and control CVD, in addition to multisector...al population-based interventions to reduce CVD risk factors in the entire population.
Methods: We describe key public health considerations in identifying and managing individuals at high risk of CVD in LMICs.
Results: A main objective of any strategy to identify individuals at high CVD risk is to maximize the number of CVD events averted while minimizing the numbers of
individuals needing treatment. Scores estimating the total risk of CVD (e.g. ten-year risk of fatal and non-fatal CVD) are available for LMICs, and are based on the main CVD risk factors (history of CVD, age, sex, tobacco use, blood pressure, blood cholesterol and diabetes status). Opportunistic screening of CVD risk factors enables identification of persons with high CVD risk, but this strategy can be widely applied in low resource settings only if cost effective interventions are used (e.g. the WHO Package of Essential NCD interventions for primary health care in low resource settings package) and if treatment (generally for years) can be sustained, including continued availability ofaffordable medications and funding mechanisms that allow people to purchase medications without impoverishing them (e.g. universal access to health care). Thisalso emphasises the need to re-orient health systems in LMICs towards chronic diseases management.
Conclusion: The large burden of CVD in LMICs and the fact that persons with high
CVD can be identified and managed along cost-effective interventions mean that
health systems need to be structured in a way that encourages patient registration, opportunistic screening of CVD risk factors, efficient procedures for the management of chronic conditions (e.g. task sharing) and provision of affordable treatment for those with high CVD risk. The focus needs to be in primary care because that is where most of the population can access health care and because CVD programmes can be run effectively at this level.
more
This document provides up-to-date guidance on laboratory studies as well as smallscale (semi-field) and large-scale field trials to assess the efficacy and determine field
application rates of new molluscicide products for control of schistosomiasis.
Un oxymètre de pouls est un petit appareil qui peut généralement être fixé sur un doigt (un orteil ou un lobe d'oreille est également possible) pour mesurer le taux d'oxygène dans le sang.
Cette méthode est totalement indolore et vous donnera un résultat en quelques secondes.
Overcoming barriers in low- and middle-income countries
For the first time, this year’s report includes information on hepatitis C diagnostics. With a focus on selected countries with diverse HCV epidemics, the report provides updates on the various dimensions of access to HCV diagnostics and pha...rmaceutical products, including product pricing, the regulatory environment and patent status, which together shape the national hepatitis response in different settings. It highlights key areas for action by ministries of health and other government decision-makers, pharmaceutical manufacturers and technical partners.
more